SARS-cov-2 / covid-19
XBiotech currently has several COVID-19 programs in place.
XBiotech is developing a True Human™ antibody therapy against SARS-CoV2, the virus that causes COVID-19, by identifying and cloning antibodies against the virus from COVID-19-recovered patients. By doing this, XBiotech is essentially harnessing the body’s natural immunity to the virus to be used as a treatment that could potentially be safe and effective—even at treating reinfection by the virus.
Recently reported research indicates that natural human antibody immunity has highly effective and lasting effects to protect against COVID-19. Researchers noted robust and long-term immunity, even in patients who only suffered mild infections of the virus. Anti-COVID-19 antibodies capable of attacking the virus were shown to remain in the body months after resolution of infections. This speaks to the enduring effects of the human body’s natural immunity—which is the source of XBiotech’s drug therapies.
True Human™ Antibody Therapeutic Antibody Treatment
XBiotech is developing a True Human™ antibody therapeutic from healthy individuals that have recovered from SARS-CoV-2 infections, in other words, from individuals that had such effective natural antibody responses that they neutralized the virus without suffering any significant illness. Identification of healthy convalescent donors with no history of severe clinical infection is a key strategy in the development of our therapies.
proprietary covid-19 Screening Technology
XBiotech has developed a screening technology to identify SARS-CoV-2 convalescent individuals with highly specific antibodies against the virus. XBiotech has transferred the technology to enable blood bank providers to identify and make SARS-CoV-2 convalescent plasma available to hospitals for treating patients sick with the disease.
COVID-19 and anti-interleukin-1alpha treatments
COVID-19 disease is associated in rare cases with an excessive inflammatory response, known as a “cytokine storm.” This can be a lethal consequence of the virus infection. Considerable scientific evidence has emerged suggesting that IL-1⍺ blockade could be effective in down regulating the inflammatory cascade associated with cytokine storm. XBiotech is developing an anti-IL-1⍺ True Human™ antibody product candidate that could be used as a disease modifying therapy in COVID-19.
FEATURED NEWS
““We have used blood samples from patients with mild infections who recovered rapidly from the virus and demonstrated very active antibody immunity against the virus. We believe that these donors make antibodies that are highly effective at protecting them against the virus. By harnessing these potent antibodies, we hope to have a highly effective treatment that has lasting protection from this devastating virus.”
”
